BI Asset Management Fondsmaeglerselskab’s Neurocrine Biosciences NBIX Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.6M	Buy	33,211 +28,714	+639%	+$4.26M	0.04%	267
2026 Q1	$592K	Sell	4,497 -3,306	-42%	-$439K	0.01%	543
2025 Q4	$1.11M	Sell	7,803 -252	-3%	-$36.5K	0.01%	499
2025 Q3	$1.13M	Buy	8,055 +3,144	+64%	+$426K	0.01%	494
2025 Q2	$617K	Sell	4,911 -26	-0.5%	-$2.98K	0.01%	574
2025 Q1	$546K	Sell	4,937 -7,385	-60%	-$936K	0.01%	556
2024 Q4	$1.68M	Sell	12,322 -4,923	-29%	-$609K	0.02%	406
2024 Q3	$1.99M	Buy	17,245 +15,818	+1,108%	+$2.17M	0.03%	285
2024 Q2	$196K	Sell	1,427 -3,510	-71%	-$481K	﹤0.01%	560
2024 Q1	$681K	Buy	4,937 +1,235	+33%	+$169K	0.01%	444
2023 Q4	$488K	Buy	3,702 +2,289	+162%	+$263K	0.01%	530
2023 Q3	$159K	Hold	1,413	–	–	﹤0.01%	639
2023 Q2	$133K	Sell	1,413 -9,457	-87%	-$924K	﹤0.01%	654
2023 Q1	$1.1M	Buy	10,870 +6,456	+146%	+$672K	0.03%	318
2022 Q4	$527K	Buy	+4,414	New	+$517K	0.01%	411
2020 Q4	–	Sell	-158	Closed	-$15K	–	456
2020 Q3	$15K	Buy	+158	New	+$18.3K	﹤0.01%	457

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's NBIX Position: Q2 2026 in Review

BI Asset Management Fondsmaeglerselskab increased its Neurocrine Biosciences (NBIX) stake by 639% in Q2 2026, buying an estimated $4.26M and bringing the position to 33,211 shares worth $5.6M. The position accounts for 0.04% of the portfolio, ranked #267.

BI Asset Management Fondsmaeglerselskab first reported a position in NBIX in Q3 2020 and has held it in 16 quarters since. 526 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

BI Asset Management Fondsmaeglerselskab held 33,211 shares of Neurocrine Biosciences worth $5.6M as of Q2 2026.
BI Asset Management Fondsmaeglerselskab bought 28,714 Neurocrine Biosciences shares in Q2 2026, an estimated $4.26M.
Neurocrine Biosciences made up 0.04% of BI Asset Management Fondsmaeglerselskab's portfolio in Q2 2026, its #267 holding.
BI Asset Management Fondsmaeglerselskab first reported a position in Neurocrine Biosciences in Q3 2020 and has held it in 16 quarters since.
526 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q2 2026, filed 10 Aug 2026.